Philippine Council for Health Research and Development

Browse over 80 requests from this government agency

Go Back
  • REQUEST SUBMITTED

    You have submitted an FOI request

    Date: 2022-02-04 18:08:51.419966

  • PROCESSING REQUEST

    Your request is already in review

  • REQUEST SUCCESSFUL

    Your request was successful

    Date: 2022-02-09 17:20:36.232379

  • 4

    RATE YOUR REQUEST

    How was your request?

DOST-Merck Ivermectin trial

Requested from PCHRD by J. Velasco at 06:08 PM on Feb 04, 2022.
Purpose: Research
Date of Coverage: 01/01/2021 - 12/31/2021
Tracking no: #PCHRD-147508359367

Velasco 06:08 PM, Feb 04, 2022

It was reported last 2021 that the Merck Ivermectin trial carried out in the quarantine centres of Ateneo de Manila University, De La Salle University, University of the Philippines Diliman and Makati Science High School will have initial data available by the end of 2021.

1. What is the progress?
2. Where to review the details?
3. Demographic data, please.

Source: https://www.pharmaceutical-technology.com/uncategorised/coronavirus-company-news-summary-philippines-to-start-ivermectin-covid-19-trial-pfizer-biontech-vaccine-benefits-outweigh-myocarditis-risk-in-young-children-fda-study-finds/

Coleto 05:20 PM, Feb 09, 2022

February 9, 2022


Dear Jayson Velasco,

Thank you for your request dated February 4, 2022, under Executive Order No. 2 (s. 2016) on Freedom of Information in the Executive Branch. Your requested information about the DOST-Merck Ivermectin Trial.

The Philippine Council for Health Research and Development (PCHRD) is one of the sectoral funding agencies of the Department of Science and Technology (DOST) that provides R&D funding for research institutions in the Philippines. PCHRD funds research proposals that are aligned with the National Unified Health Research Agenda (NUHRA) and Harmonized National Research and Development Agenda (HRNDA).

In response to your questions, we are currently applying to the Single Joint Research Ethics Board (SJREB) and University of the Philippines Manila Research Ethics Board (UPMREB), and Food and Drug Administration (FDA) for ethics and clinical trial clearances, respectively. The study will commence once these are obtained. Hence, we cannot share any information yet as the ethics and clinical trial review are underway. 

If you are unhappy with this response to your FOI request, you may ask us to carry out an internal review of the response by writing to our Executive Director, Dr. Jaime C. Montoya, at jcmontoya@pchrd.dost.gov.ph. Your review request should explain why you are dissatisfied with this response and should be made within 15 calendar days from the date when you received this letter. We will complete the review and tell you the result within 30 calendar days from the date when we receive your review request.

If you are not satisfied with the result of the review, you then have the right to appeal to the Office of the President under Administrative Order No. 22, s. 2011.

Thank you.

Respectfully yours,


Janneth Coleto
DOST-PCHRD FOI Receiving Officer

Is this request offensive?

Requests for personal information and vexatious requests are not considered valid requests for Official Information.

If you believe this request is not suitable, you can report it for attention by the site administrators.